BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/11/2018 10:51:26 AM | Browse: 1422 | Download: 2207
 |
Received |
|
2018-03-20 02:44 |
|
Peer-Review Started |
|
2018-03-20 07:29 |
|
First Decision by Editorial Office Director |
|
2018-04-02 23:16 |
|
Return for Revision |
|
2018-04-10 11:26 |
|
Revised |
|
2018-04-12 10:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-04-23 05:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-04-23 16:32 |
|
Articles in Press |
|
2018-04-23 16:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-05-10 08:54 |
|
Publish the Manuscript Online |
|
2018-05-11 10:51 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
New therapeutic options opened by the molecular classification of gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mihaela Chivu-Economescu, Lilia Matei, Laura Georgiana Necula, Denisa Laura Dragu, Coralia Bleotu and Carmen Cristina Diaconu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mihaela Chivu-Economescu, PhD, Senior Researcher, Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Ave, Bucharest 030304, Romania. mihaela.economescu@virology.ro |
| Key Words |
Gastric cancer; Molecular classification; Immunotherapy; Targeted therapy; Clinical trials |
| Core Tip |
A new molecular classification of gastric cancer (GC) became available after publication of three landmark studies: The Cancer Genome Atlas, “Singapore-Duke” study, and Asian Cancer Research Group, allowing patient selection for specific targeted therapy. The Epstein-Barr virus positive, microsatellite stable TP53-active or microsatellite-unstable tumors subtypes presents tumour infiltrating patterns with overexpression of PD-1, PD-L1, PDL-2. Preliminary data show high response rate to immunotherapy and open new avenues to gene therapy. Currently effective therapies for diffuse GC are lacking. Mutations in e-cadherin and Ras homolog family member A genes, or Claudin-18-ARHGAP6/26 fusions may be exploited as therapeutic targets. The only targeted therapies approved so far for chromosomal instability and microsatellite stable TP53-inactive subtypes of GC are trastuzumab and ramucirumab (HER2 and VEGFR2 inhibitors). |
| Publish Date |
2018-05-11 10:51 |
| Citation |
Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. World J Gastroenterol 2018; 24(18): 1942-1961 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i18/1942.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i18.1942 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
